Open house Arzneimittelrabattverträge Apremilast, ATC L04AA32
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Apremilast, ATC L04AA32
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
25 / 100
Risk factors
No estimated value or guaranteed volume; actual revenue depends on market share and prescriptions in Bavaria.
If a formal rebate contract (via open procedure) for Apremilast is concluded, the open house agreements automatically t...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jun 2027
- Supply of pharmaceutical products containing Apremilast (ATC L04AA32) under non-exclusive rebate agreements with AOK Bayern
- Contract terms are identical for all participants, no individual negotiation
Show full summary
Open house model for non-exclusive pharmaceutical rebate agreements (Rabattverträge) for the active substance Apremilast (ATC L04AA32) by AOK Bayern. This is not a formal procurement procedure but a voluntary accession model under §130a Abs. 8 SGB V. Any interested pharmaceutical company meeting eligibility criteria can conclude a standardized, non-negotiable rebate contract. Contracts can be concluded at any time until 05.05.2027, with earliest start 01.07.2025 and latest end 30.06.2027. No estimated value provided. Only one lot covering the product.
Risks
No estimated value or guaranteed volume; actual revenue depends on market share and prescriptions in Bavaria.
If a formal rebate contract (via open procedure) for Apremilast is concluded, the open house agreements automatically t...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Eligibility: Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible
Administrative
- Submission of signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submission of signed contract and appendix specifying the medicinal products
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Apremilast, ATC L04AA32
Non-exclusive rebate agreements for pharmaceutical products containing Apremilast (ATC L04AA32). All interested pharmaceutical companies meeting eligibility can join. Standardized terms, no negotiation.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 15 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 318281-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
25 / 100
Risk factors
No estimated value or guaranteed volume; actual revenue depends on market share and prescriptions in Bavaria.
If a formal rebate contract (via open procedure) for Apremilast is concluded, the open house agreements automatically t...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications